Friday, July 10, 2026
🇺🇸 FDA

pharma · Diabetes · Congenital Bleeding Disorder

Novo Nordisk A/S

Novo Nordisk A/S clinical programs — 40 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Novo Alle, Bagsværd, 2880, DK
Founded
1923
Employees
63,033
Programs
40
Drugs
46
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Novo Nordisk A/S projects

40 ClinicalTrials.gov programs sponsored by Novo Nordisk A/S.

Novo Nordisk A/S has 40 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

40 programs

Clinical programs

  1. CHRD 2419

    Novo Nordisk A/S

    Cardiorespiratory arrest at birth in full-term newborns

    phase 3 small molecule active

    1 trial

  2. Cagrilintide

    Novo Nordisk A/S

    Overweight

    phase 3 small molecule completed

    1 trial

  3. Concizumab

    Novo Nordisk A/S

    Haemophilia A Without Inhibitors

    phase 3 small molecule active

    1 trial

  4. Concizumab

    Novo Nordisk A/S

    Haemophilia A With Inhibitors

    phase 3 small molecule active

    1 trial

  5. EF-41/KEYNOTE D58

    Novo Nordisk A/S

    Newly diagnosed Glioblastoma

    phase 3 small molecule active

    1 trial

  6. Faster-acting insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  7. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  8. Insulin icodec

    Novo Nordisk A/S

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  9. NNC0487-0111

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  10. Oral semaglutide

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  11. Semaglutide

    Novo Nordisk A/S

    Overweight

    phase 3 small molecule completed

    1 trial

  12. Somapacitan

    Novo Nordisk A/S

    Growth Hormone Deficiency in Children

    phase 3 small molecule completed

    2 trials

  13. Tecentriq 840 mg concentrate for solution for infusion

    Novo Nordisk A/S

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 3 small molecule active

    1 trial

  14. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo Nordisk A/S

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  15. Ziltivekimab

    Novo Nordisk A/S

    Heart Failure

    phase 3 small molecule active

    1 trial

  16. biphasic insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  17. eptacog alfa (activated)

    Novo Nordisk A/S

    Acquired Bleeding Disorder

    phase 3 small molecule completed

    1 trial

  18. insulin degludec

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  19. liraglutide

    Novo Nordisk A/S

    Metabolism and Nutrition Disorder

    phase 3 small molecule completed

    1 trial

  20. liraglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  21. nonacog beta pegol

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 3 small molecule completed

    1 trial

  22. rosiglitazone

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule terminated

    1 trial

  23. semaglutide

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    4 trials

  24. somapacitan

    Novo Nordisk A/S

    Growth Hormone Disorder

    phase 3 small molecule completed

    1 trial

  25. turoctocog alfa pegol

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 3 small molecule completed

    2 trials

  26. LY2140023

    Novo Nordisk A/S

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  27. Matched Placebo

    Novo Nordisk A/S

    Mechanical allodynia

    phase 2 small molecule active

    1 trial

  28. NNC6019-0001

    Novo Nordisk A/S

    Transthyretin Amyloid Cardiomyopathy (ATTR CM)

    phase 2 small molecule completed

    1 trial

  29. Product

    Novo Nordisk A/S

    Women with an indication for IVF/ICSI

    phase 2 small molecule active

    1 trial

  30. activated recombinant human factor VII

    Novo Nordisk A/S

    Acquired Bleeding Disorder

    phase 2 small molecule completed

    2 trials

  31. Faster Aspart

    Novo Nordisk A/S

    Diabetes Mellitus, Type 1

    phase 1 small molecule completed

    1 trial

  32. NNC 0172-0000-2021

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 1 small molecule completed

    1 trial

  33. NNC0480-0389

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  34. To evaluate the pharmacokinetics and safety of nolasiban

    Novo Nordisk A/S

    not applicable (submitted trial is a pharmacokinetic study in healthy subjects)

    phase 1 other active

    1 trial

  35. KCT02/2023-SATELLITE

    Novo Nordisk A/S

    Arterial hypertension

    approved small molecule active

    1 trial

  36. KCT10/2022-LEASH

    Novo Nordisk A/S

    Hyperlipidaemia

    approved small molecule active

    1 trial

  37. KCT23/2022-ZOOM-IN

    Novo Nordisk A/S

    Knee osteoarthritis

    approved small molecule active

    1 trial

  38. biphasic insulin aspart 30

    Novo Nordisk A/S

    Diabetes

    approved small molecule completed

    2 trials

  39. insulin detemir

    Novo Nordisk A/S

    Diabetes

    approved small molecule completed

    2 trials

  40. turoctocog alfa

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    approved small molecule completed

    2 trials

Frequently asked questions

How many clinical projects does Novo Nordisk A/S have?

40 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.